Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth MCES Treatment Setting Prior Auth | Op…
    Ask Trek AI about this page
    CurrentAmeriHealthPolicy N/A

    Most Cost-Effective Setting (MCES) Program Drug List — Treatment Setting Precertification

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the AmeriHealth MCES program that requires precertification of the treatment setting for certain medical-benefit medications to ensure safety and cost-effectiveness; affects providers requesting coverage for listed drugs under the AmeriHealth medical benefit in North Carolina.

    Policy Summary
    PayerAmeriHealth
    PolicyMost Cost-Effective Setting (MCES) Program Drug List — Treatment Setting Precertification
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2012
    Next Review DateN/A
    Key ActionObtain precertification of the treatment setting for medications on the MCES list before providing services.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2012Program established
    >=100Drugs listed
    IVIG/SCIGClass added

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2012-01-01
    Effective metadata

    Coverage Criteria

    The list identifies medications included in AmeriHealth’s Most Cost-Effective Setting (MCES) Program and is subject to change. Providers should confirm the current MCES Drug List at the time of precertification because additions or removals may occur.

    All generics and biosimilars to a reference product on this list are included in the program and are subject to precertification review to determine the most cost‑effective and clinically appropriate treatment setting.

    Provider Actions & Requirements

    Prior Authorization

    Precertification for treatment setting

    Medications listed on the Most Cost-Effective Setting (MCES) Drug List require pre-certification of the treatment setting before services are provided. AmeriHealth must approve the treatment setting as part of the precertification process to confirm the requested setting is medically appropriate and cost-effective.

    • Applies to all drugs on the MCES Drug List.
    • Requests must be submitted prior to the planned service date to avoid potential denials or retroprocessing.
    Documentation Required

    Precertification documentation

    Providers must submit complete precertification documentation that supports the requested treatment setting. Documentation should allow AmeriHealth to determine that the member meets applicable medical policy criteria and that the setting requested is the most appropriate and cost-effective.

    • Include clinical notes, diagnosis, prior treatments, rationale for the requested setting, and any relevant lab or imaging results.
    • Incomplete or missing documentation may result in delays, denial, or retroactive processing of the claim.
    Note

    Biosimilars/generics review

    All generics and biosimilars to a reference product included in the MCES Program are subject to the same precertification review for treatment setting as their reference biologic or branded product. Providers must request precertification for these agents as well.

    • Biosimilars and generics will be reviewed to ensure the same clinical and setting criteria are met.
    • Addition of a product to the MCES list (including within a drug class added on a prior date) makes the precertification requirement effective for that product.
    Denial Risk

    Precertification required

    Requests for treatment settings for medications on the MCES list that do not obtain required precertification may be denied or subject to retroprocessing. Providers should verify precertification approval before delivering services.

    • Failure to precertify may result in claim denial or payment adjustments.
    • Check the current MCES Drug List for products and effective dates before submitting a request.

    Definitions

    Most Cost-Effective Setting (MCES) Program — definition and purpose
    Program nameMost Cost-Effective Setting (MCES) Program
    PurposeRequires AmeriHealth approval of the treatment setting for certain medications covered under the AmeriHealth medical benefit to ensure the setting is safe and cost‑effective and to manage total cost of care.
    When review occursThe review is conducted as part of the precertification process.
    ScopeApplies to medications listed on the MCES Drug List and includes entire drug classes where specified.
    Program established2012
    IVIG/SCIG — class addition and inclusion in MCES

    Site of Care Requirements

    Prior Authorization

    Infusion center setting requires approval

    The requested treatment setting (for example, an infusion center) for MCES‑listed medications must be approved by AmeriHealth as part of the precertification process to ensure cost‑effectiveness and safety.

    • Do not schedule administration in the setting until precertification approval is obtained.

    Biosimilar & Generic Guidance

    Billing Rule

    Biosimilars/generics require precertification review

    All generics and biosimilars to a reference product in this program are subject to precertification review to determine the most cost‑effective setting before coverage is authorized.

    Step Therapy / Review Rules

    Drug / ProductCoverage note
    All generics and biosimilars to a reference product in the MCES ProgramSubject to precertification review for most cost‑effective setting
    IVIG/SCIG drug class (intravenous/subcutaneous immunoglobulin)Included in MCES Program effective January 1, 2012; all products in this class are subject to precertification review for most cost‑effective setting
    Individual listed products (examples include Veopozt, Vimizim, VPRIV, Vyepti, Vyvgart, Wezlana, Xbryk, Xembify, Xolaire, Yesintek, Yimmugo, Zemaira)Listed products are included on the MCES Drug List and are subject to treatment‑setting precertification; the list is subject to change

    Background

    The MCES Program evaluates and approves the treatment setting in which certain medical‑benefit drugs are administered to manage total cost of care while ensuring safety and adherence to AmeriHealth policy. Program review is performed as part of the precertification process.

    The intravenous/subcutaneous immunoglobulin class (IVIG/SCIG) was added to the MCES Program effective January 1, 2012; program requirements therefore apply to all drugs in that class regardless of individual FDA approval dates.

    Policy Summary
    PayerAmeriHealth
    PolicyMost Cost-Effective Setting (MCES) Program Drug List — Treatment Setting Precertification
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2012
    Next Review DateN/A
    Key ActionObtain precertification of the treatment setting for medications on the MCES list before providing services.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions & RequirementsDefinitionsSite of Care RequirementsBiosimilar & Generic GuidanceStep Therapy / Review RulesBackground
    Class added
    Intravenous/subcutaneous immunoglobulin (IVIG/SCIG)
    Effective date for classJanuary 1, 2012
    Applicability noteProgram requirements apply to all drugs in the IVIG/SCIG class regardless of individual FDA approval dates — the January 1, 2012 date indicates when requirements went into effect for the class.
    Related operational impactAll generics and biosimilars to a reference product in this program (including IVIG/SCIG) are subject to precertification review for most cost‑effective setting.